Drug intelligence / Profile preview

Cynovit

Development stage: Unknown
Lead developer: Merlin Pharmaceuticals
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

Cynovit is an injectable formulation of cyanocobalamin (vitamin B12) developed and marketed by Merlin Pharmaceuticals. As a synthetic form of vitamin B12, it serves as a crucial cofactor for enzymes involved in DNA synthesis, hematopoiesis, and neurological function. It is primarily indicated for the treatment of pernicious anemia, vitamin B12 deficiency due to malabsorption, and other macrocytic anemias. The drug is administered via intramuscular or subcutaneous injection to bypass gastrointestinal absorption issues often associated with B12 deficiency.

Brand names: Cynovit
Other names: cyanocobalamin injection

Targets

MTR (Methionine synthase)MMUT (Methylmalonyl-coenzyme A mutase)

Beyond the preview

Go deeper on Cynovit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cynovit.

Explore the full profile